Term
| Prostate cancer treatment for locally advances |
|
Definition
| radiation + hormone (goselin) |
|
|
Term
| what regimen for locally advanced prostate |
|
Definition
|
|
Term
| Prostate positive DRE, how to responde |
|
Definition
| always TRUS and biopsy. also, always perform TRUS and biopsy w/PSA > 10 |
|
|
Term
|
Definition
| 2-4, well differentiated, 5-6, moderate margins, 7-10 poorly differentiated |
|
|
Term
| prostate cancer treatment for metastatic disease |
|
Definition
| palliative care: hormone deprivation w/antiandrogens or LHRH agonists/antagonists |
|
|
Term
| palliative care with antiandrogens (overview) |
|
Definition
| most effective in combination therapy, reduces flare risk, |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| non steroidal antiandrogen |
|
|
Term
|
Definition
| non steroidal antiandrogen |
|
|
Term
|
Definition
| non steroidal antiandrogen; many SE, not used often |
|
|
Term
|
Definition
| LHRH antagonist; reduces testosterone to castration levels, can cause QT prolongation; no risk of tumor flare |
|
|
Term
| definition of hormone refractory prostate cancer |
|
Definition
| increasing PSA or symptomatic progression |
|
|
Term
| supportive care in hormone refractory prostate cancer |
|
Definition
| prednisone and/or dexamethasone |
|
|
Term
| hormone refractory prostate cancer regimens w/prednisone |
|
Definition
| mitoxantrone, docetaxel, cazitaxel |
|
|
Term
| hormone refractory prostate cancer regimens w/estramustine |
|
Definition
| vinblastine, etoposide, docetaxel, |
|
|
Term
| hormone refractory prostate cancer regimens w/o prednisone or estramustine |
|
Definition
| ketoconazole and doxorubicin; sipuleucel-T (Immunotherapy) |
|
|
Term
|
Definition
| anthracenedione; dose adjust on hepatic function; can cause cardiac events |
|
|
Term
|
Definition
| nitrogen-mustard-estradiol; inhibits microtubules; can cause fluid retention, gynecomastia |
|
|
Term
| preferred regimen in hormone resistant prostate cancer |
|
Definition
| docetaxel,prednisone, bevacizumab |
|
|
Term
|
Definition
| immunotherapy; autologous CD 54+; for minimally symptomatic refractory prostate cancer |
|
|
Term
|
Definition
| microtubule inhibitor; premedicate w/diphenhydramine, dexamethasone, ranitidine; approved for docetaxel failed patients |
|
|
Term
|
Definition
| platinum-based chemo; no renal impairment or neuropathy; limited myelosuppression; for refractory prostate cancer, no survival benefit but superior time to progression |
|
|
Term
| tx for bone metastasis in prostate cancer |
|
Definition
| zolendronic acid or denosumab |
|
|
Term
|
Definition
| surgery or radiation, survival 67% |
|
|
Term
|
Definition
| surgery w/chemo; survival ~ 40% |
|
|
Term
| NSCLC stage III resectable tx |
|
Definition
| surgery w/chemo; survival ~ 20% |
|
|
Term
| NSCLC stage III non-resectable or stage IV tx |
|
Definition
| chemradiotherapy or chemotherapy; survival ~ 3% |
|
|
Term
| indication for radiotherapy in NSCLC |
|
Definition
| postoperative w/positive margins; chemoradiotherapy in unresectable stage III |
|
|
Term
| chemotherapy indications in NSCLC |
|
Definition
| stage II and IIIa w/cisplatin-based regimen |
|
|
Term
| preferred chemo regimen in NSCLC |
|
Definition
|
|
Term
| NSCLC stage IIIb non-resectable preferred regimen |
|
Definition
| cisplatin/etoposide w/radiotherapy |
|
|
Term
| how to treat NSCLC stage IIIb nonresectable w/pleural effusion |
|
Definition
| follow stage IV guidelines |
|
|
Term
| NSCLC stage IV first line tx |
|
Definition
| cisplatin/pemetrexed in PS 0,1 |
|
|
Term
| indication for bevacizumab in stage IV NSCLC |
|
Definition
| adjunct to carboplatin/paclitaxel |
|
|
Term
| indication for cetuximab in NSCLC stage IV |
|
Definition
| adjunct to cisplatin/vinorelbine in EGFR-positive tumor |
|
|
Term
| when is erlotinib/gefitinib 1st line in NSCLC stage IV |
|
Definition
| in patients w/EGFR mutations regardless of PS |
|
|
Term
| NSCLC tx in PS 2,3,4 stage IV |
|
Definition
| single regimen tx in PS 2, no chemo in >2 |
|
|
Term
| second line tx for NSCLC stage IV |
|
Definition
| docetaxel or pemetrexed or erlotinib, may want to reserve erlotinib for 3rd line |
|
|
Term
| which genetic marker is routinely checked in NSCLC |
|
Definition
| EGFR which is overexpressed in 80% |
|
|
Term
| best time to progression among NSCLC IIIb or IV tx |
|
Definition
| cisplatin and gemcitabine; also highest rate of thrombocytopenia |
|
|
Term
| 1st line for NSCLC squamous cell |
|
Definition
|
|
Term
|
Definition
| for locally advanced or metastatic non-squamous NSCLC; contraindicated CrCl<45; coadminister folic acid + B12 |
|
|
Term
|
Definition
| dose limiting nephrotoxicity, administer w/significant fluids, contraindicated Cr > 1.5; N/V; |
|
|
Term
|
Definition
| dose-limiting myelosuppression |
|
|
Term
|
Definition
| -25% dose if CrCl<50; -50% if CrCl<10 |
|
|
Term
|
Definition
|
|
Term
|
Definition
| fluid retention; avoid if bilirubin >1.5 |
|
|
Term
|
Definition
| elevates liver enzymes; relative contraindication in severe hepatic/renal |
|
|
Term
|
Definition
| reduce dose by 1/2 if bilirubin >2, by 75% if bilirubin >3 |
|
|
Term
|
Definition
| contraindicated w/bleed risk (hemoptysis); add to carboplatin/paclitaxel for OS and RR (bleed risk); contraindicated w/squamous cell; CNS metastasis |
|
|
Term
| indication for cetuximab in NSCLC |
|
Definition
| IIIb and IV w/cisplatin and vinorelbine; rash predicted of better outcome |
|
|
Term
|
Definition
| indicated for all EGFR mutation(?); may cause hepatic failure; gefitinib has similar efficacy |
|
|
Term
|
Definition
| grade 1: hydrocortisone; grade 2: fluticasone or oral steroid for multiple rashes; grade 3: oral methylprednisolone |
|
|
Term
| maintenance therapy for non-squamous NSCLC |
|
Definition
|
|
Term
| maintenance therapy for squamous NSCLC |
|
Definition
|
|
Term
|
Definition
| etoposide/cisplatin; etoposide/carboplatin; cyclophosphamide/doxyrubicin/vincristine; |
|
|
Term
|
Definition
| topo I inhibitor; myelosuppression dose limiting; reduce dose by 50% if CrCl 20-40; approved for relapsed SCLC w/response to primary therapy 45 days out |
|
|
Term
|
Definition
| cell cycle non-specific nitrogen mustard;cytotoxic, disrupts DNA; extravasation risk; sodium thiosulfate used for antidote |
|
|
Term
|
Definition
| alylating agent; used for multiple myeloma |
|
|
Term
|
Definition
| alkylating agent; used for chronic lymphocytic leukemia |
|
|
Term
|
Definition
|
|
Term
|
Definition
| formed by ifosfamide, causes hemorrhagic cystitis |
|
|
Term
|
Definition
| alkylating agent used in testicular cancer |
|
|
Term
| 1st line therapy for stage III colorectal cancer |
|
Definition
| FOLFOX; oxaliplatin, 5-FU/leucovorin |
|
|
Term
| 5-FU regimen for stage III colon cancer |
|
Definition
| LV/5-FU bolus days 1-5, repeat @ 4 weeks |
|
|
Term
|
Definition
| converted to 5-FU enzymatically; equivalent to 5-FU in stage III colorectal cancer |
|
|
Term
|
Definition
| rescue therapy for 5-FU, prevents dose limiting incorporation of 5-FU into RNA through enzymatic conversion to uridine |
|
|
Term
|
Definition
| alkylating agent; used in chronic lymphoctyic leukemia |
|
|
Term
|
Definition
| platinum based; generally well tolerated; causes neurotoxicity; acute 56%, resolves 2 weeks; avoid cold air/drink; if chronic need glutathione for tx |
|
|
Term
|
Definition
| nitrosourea; lipophilic, cross BBB; crosslink DNA and disable repair enzyme |
|
|
Term
|
Definition
| nitrosourea used in islet cell carcinoma |
|
|
Term
| bevacizumab role in stage III colorectal cancer |
|
Definition
| unclear, provides benefit in first two years of tx |
|
|
Term
| first line tx for metastatic colorectal cancer |
|
Definition
FOLFOX + bevacizumab/switch bev to cetuximab in KRAS wild type.
oxaliplatin + irinotecan 2nd line +/- bev
a couple of other options |
|
|
Term
|
Definition
| topo I inhibitor; active metabolite is SN 38; ketoconazole increases this reaction, st. john's wort decreases it; infusion-related diarrhea managed w/atropine |
|
|
Term
|
Definition
|
|
Term
|
Definition
| cannot be combined, cetuximab only works with native KRAS. cetuximab works well w/KRAS wild type |
|
|
Term
|
Definition
| recombinant EGFR monoclonal antibody; indicated last line in wild type KRAS mCRC for improved PFS (not OS) after failure of fluoropyrimidine, oxaliplatin, irinotecan |
|
|
Term
| maximum BSA for dosing chemo drugs |
|
Definition
|
|
Term
| what are the risks w/intrathecal infusion |
|
Definition
| drug cannot be removed or reversed once administered. always a time out for intrathecal administrations |
|
|
Term
| with multidrug regimens when are taxanes administered |
|
Definition
| first (pay your taxes first) |
|
|
Term
|
Definition
| cisplatin, dacarbazine, dactinomycin, daunorubicin, doxorubicin, epirubicin, idrarubicin, mechlorethamine, mitomycin c, stroptazosin, vinblastine, vincristine, vindesine, vinorelbine |
|
|
Term
| risk factors for extravasation |
|
Definition
| age, vasculature, education, skill of practicioner, method of administration |
|
|
Term
|
Definition
| avoid extremities, poorly vascularized regions, central if possible, |
|
|
Term
| cisplatin remedy for extravasation |
|
Definition
|
|
Term
| most likely female cancers by age |
|
Definition
| <20: leukemia, <60 breast, >60 lung |
|
|
Term
| pemetrexed role in stage III/IV lung cancer |
|
Definition
| maintenance or initial tx w/cisplatin for non-squamous NSCLC |
|
|
Term
| APL (promyelocytic acute leukemia) tx |
|
Definition
| add ATRA; causes tumor lysis syndrome so monitor for coaguolopathies |
|
|
Term
| 1st line treatment for acute myeloid leukemia |
|
Definition
| &+3 cytarabine for 7 days, anthracycline (daunorubicin, idrarubicin, mitoxantrone) for 3 days |
|
|
Term
|
Definition
|
|
Term
|
Definition
| topotecan; myelosuppression, caution in renal |
|
|
